Poolbeg Pharma (POLB) Company Presentation summary

Investment highlights and strategy

• Highly experienced leadership and board with proven track record in life sciences and deal-making.

• Three high-value programmes targeting critical unmet medical needs in oncology, obesity, and infectious diseases.

• Multiple near-term clinical value inflection points and strong partnering potential in areas of high industry interest.

• Cash runway into 2027, fully funded through key clinical milestones in oncology and obesity.

• Partnering-focused model with cost-effective trials designed to accelerate value creation and shareholder returns.

POLB 001: Oncology and CRS prevention

• POLB 001 is an orally delivered, selective p38 MAPK inhibitor for preventing cancer immunotherapy-induced Cytokine Release Syndrome (CRS).

• Addresses a >$10B market opportunity with no approved preventative therapies for CRS; over 70% of patients on certain therapies experience CRS.

• Demonstrated strong preclinical and clinical data, including potent inhibition of key inflammatory markers and favorable safety profile.

• Awarded FDA Orphan Drug Designation, providing 7 years US exclusivity and other regulatory benefits.

• Phase 2a trial in relapsed/refractory multiple myeloma patients expected to start H2 2025, with topline data in H2 2026.

Market opportunity and impact

• Rapid growth in bispecific antibody and CAR T-cell therapy markets, with CRS as a major limiting factor for broader adoption.

• Effective CRS prevention could enable outpatient administration and expand access to cancer immunotherapies.

• Addressable population of ~500,000 patients in US and EU5 for DLBCL and MM alone by 2030.

• POLB 001 could remove treatment bottlenecks and facilitate wider patient access.